Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effects of Video-Based Education on Symptom Management Self-Efficacy and Quality of Life in Women Receiving Chemotherapy for Breast Cancer

10 de novembro de 2026 atualizado por: Antalya Bilim University

The Effect of a Video-Based Educational Intervention on Symptom Management Self-Efficacy and Quality of Life in Women With Breast Cancer Receiving Chemotherapy

This study is designed as a randomized controlled trial to evaluate the effect of a video-based educational intervention on symptom management self-efficacy and quality of life in women diagnosed with breast cancer who are receiving chemotherapy. The study will be conducted at the Day Chemotherapy Unit of Akdeniz University Hospital. The study sample will consist of female patients diagnosed with breast cancer who meet the inclusion criteria and consent to participate. Participants will be divided into two groups: an intervention group and a control group.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

This study is designed as a randomized controlled trial to evaluate the impact of a video-based educational intervention on self-efficacy for symptom management and quality of life in women diagnosed with breast cancer who are undergoing chemotherapy. The study will be conducted at the Day Chemotherapy Unit of Akdeniz University Hospital. The study sample will consist of women diagnosed with breast cancer who meet the inclusion criteria and consent to participate. Participants will be assigned to either an intervention group or a control group. The sample size was calculated using the G*Power 3.1.9 software, determining that a minimum of 72 participants-36 in each group-are required. Accounting for potential attrition, the study is planned to include a total of 90 participants, with 45 in the intervention group and 45 in the control group. In addition to routine care, patients in the intervention group will receive support for symptom management through a video-based educational intervention over a period of 8 weeks. Patients in the control group will receive the standard routine care provided at the study site. Data will be collected at three time points: baseline (T0), an interim follow-up (T1), and a final post-test (T2). The primary outcomes of the study are the level of self-efficacy regarding chemotherapy symptom management and quality of life. Secondary outcomes include the usability of the video-based educational intervention and instances of unplanned healthcare utilization (such as emergency department visits or unplanned hospital readmissions). Data collection will involve the use of a "Patient Information Form," the "Chemotherapy Symptom Management Self-Efficacy Scale for Breast Cancer," the "Functional Assessment of Cancer Therapy - Breast (FACT-B)," the "System Usability Scale," and a "Healthcare Utilization and Readmission Form" developed by the researcher. Data obtained from the study will be analyzed using the SPSS software package. It is anticipated that the video-based educational intervention will increase self-efficacy in symptom management among women diagnosed with breast cancer, improve their quality of life, and reduce the utilization of healthcare services, such as emergency department visits and hospital readmissions.

Tipo de estudo

Intervencional

Inscrição (Estimado)

90

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Being 18 years of age or older,
  • Being able to read and write in Turkish,
  • Having no barriers to written or verbal communication,
  • Being newly diagnosed with breast cancer and being aware of the diagnosis,
  • Having received at least two cycles of chemotherapy,
  • Having access to an internet-enabled digital device (e.g., smartphone), either personally owned or shared with family members, and being able to use it actively,
  • Having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.

Exclusion Criteria:

  • Patients who do not agree to participate in the study,
  • Patients participating in another study related to symptom management,
  • Patients with a history of diagnosed psychiatric disorders,
  • Patients with an Eastern Cooperative Oncology Group (ECOG) Performance Status of 3 or higher.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: INTERVENTION GROUP

In addition to routine care, patients in the intervention group will receive symptom management support over an 8-week period through a video-based educational intervention.

Participants in the intervention group will receive an 8-week video-based educational intervention in addition to standard care. The web-based platform will provide evidence-based educational videos on chemotherapy-related symptoms and symptom management. Participants will be directed to symptom-specific videos through a rule-based algorithm based on their self-reported symptoms. They will be asked to access the platform at least three times per week and will receive reminder messages twice weekly. Platform usage will be monitored, and post-intervention assessments will be conducted after the 8-week intervention.

Sem intervenção: CONTROL GROUP

Patients in the control group will receive the routine care provided at the center where the study is being conducted.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Self-Efficacy Scale for Breast Cancer Related to Chemotherapy (SMSES-BC)
Prazo: Baseline (T0), Week 4 (T1), and Week 8 (T2).

Symptom management self-efficacy will be assessed using the Symptom Management Self-Efficacy Scale for Breast Cancer Related to Chemotherapy (SMSES-BC). Changes in self-efficacy scores will be evaluated across three assessment points.

Baseline (T0), Week 4 (T1), and Week 8 (T2).
Functional Assessment of Cancer Therapy-Breast (FACT-B)
Prazo: Baseline (T0), Week 4 (T1), and Week 8 (T2).

Quality of life will be assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B). Changes in quality-of-life scores will be evaluated across three assessment points.

Baseline (T0), Week 4 (T1), and Week 8 (T2).

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
System Usability Scale (SUS)
Prazo: At the end of the intervention (T2).

System usability will be assessed in the intervention group using the System Usability Scale (SUS) to evaluate participants' perceptions of the video-based educational platform.

At the end of the intervention (T2).
Hospital Readmissions
Prazo: Week 8 (T2), covering the previous 8 weeks.

Hospital readmissions will be assessed using a researcher-developed healthcare utilization form, including the occurrence, frequency, and duration of hospital readmissions during the 8-week study period.

Week 8 (T2), covering the previous 8 weeks.
Emergency Department Visits
Prazo: Week 8 (T2), covering the previous 8 weeks.

The number and reasons for emergency department visits during the 8-week study period will be assessed using a researcher-developed healthcare utilization form.

Week 8 (T2), covering the previous 8 weeks.
Unplanned Healthcare Visits
Prazo: Week 8 (T2), covering the previous 8 weeks.

The frequency and reasons for unplanned outpatient clinic visits and other healthcare facility visits will be assessed using a researcher-developed healthcare utilization form.

Week 8 (T2), covering the previous 8 weeks.
Treatment-Related Economic Burden
Prazo: Week 8 (T2), covering the previous 8 weeks.

Treatment-related economic burden will be assessed using a researcher-developed form to evaluate the financial burden associated with healthcare utilization during the study period.

Week 8 (T2), covering the previous 8 weeks.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Ümmühan Duman, Antalya Bilim University- ummuhan.duman@antalya.edu.tr

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de dezembro de 2026

Conclusão Primária (Estimado)

1 de fevereiro de 2027

Conclusão do estudo (Estimado)

1 de maio de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

10 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de novembro de 2026

Primeira postagem (Real)

16 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • ABU_HEM_ÜD_2026

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .